The drugs are Pfizer’s Corvert and vincristine sulfate injection.
Corvert is an anti-arrhythmic heart drug used to treat atrial fibrillation or atrial flutter. Vincristine is a chemotherapy drug, used mostly in childhood cancers.
Both drugs are currently facing shortages, so ProvideGx and Pfizer’s partnership aims to create a long-term supply of the two drugs for hospitals.
ProvideGx said it has a list of more than 50 other drugs currently in shortage it plans to supply in the future.
The financial details of ProvideGx and Pfizer’s partnership weren’t disclosed.
Read the full news release here.
More articles on pharmacy:
21 states reject $18B opioid settlement offer from McKesson, Cardinal, AmerisourceBergen
BCBS responds to physician pushback on mail-order pharmacy plan
The 20 most expensive drugs in the US in 2020
